Annotation Detail
Information
- Associated Genes
- MET
- Associated Variants
-
MET EXON 14 SKIPPING MUTATION
MET EXON 14 SKIPPING MUTATION - Associated Disease
- lung adenocarcinoma
- Source Database
- CIViC Evidence
- Description
- We now report responses to the MET inhibitors crizotinib and cabozantinib in four patients with stage IV lung adenocarcinomas harboring mutations leading to MET exon 14 skipping.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/797
- Gene URL
- https://civic.genome.wustl.edu/links/genes/52
- Variant URL
- https://civic.genome.wustl.edu/links/variants/324
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Lung Adenocarcinoma
- Evidence Direction
- Supports
- Drug
- Crizotinib
- Evidence Level
- C
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 25971939
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Crizotinib | Sensitivity | true |